profit from every $100 of sales.
$0$100
Stryker
$309.64-0.88% today
-17.1% in 1 year
1-year low $269.751-year high $387.46
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $36.31 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Stryker sold, what it kept, and what it did with the cash.
Sales went from $18.4 billion in 2022 to $25.1 billion in 2025, with $3.25 billion of profit last year.
SalesProfit
Stryker handed back 30% of the cash it generated last year.
$1.3B
Free cash flow 2025$4.3B
Bought back its own shares–
Paid as dividends$1.3B
Cash vs. debt$4.0B vs. $15.9B
Stryker vs. similar companies
Stryker grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Stryker | 36.3× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Edwards Lifesciences | 57.4× · Expensive | ||
 Siemens Healthineers | 25.3× · Fair price |
Compare Stryker with AbbVie · Boston Scientific · Johnson & Johnson · Eli Lilly · 3M · Merck & · Roche · Thermo Fisher Scientific
AI analysis
An AI analyst reads Stryker's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 14,351 | 17,108 | 18,449 | 20,498 | 22,595 | 25,116 | |
| 9,057 | 10,968 | 11,578 | 13,058 | 14,440 | 16,065 | |
| 2,223 | 2,584 | 3,111 | 3,924 | 4,666 | 5,059 | |
| 3,081 | 3,608 | 4,109 | 5,064 | 4,951 | 6,314 | |
| 1,599 | 1,994 | 2,358 | 3,165 | 2,993 | 3,246 | |
| 4.20 | 5.21 | 6.17 | 8.25 | 7.76 | 8.40 | |
| 63.1% | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% | |
| 15.5% | 15.1% | 16.9% | 19.1% | 20.7% | 20.1% | |
| 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 34,330 | 34,631 | 36,884 | 39,912 | 42,971 | 47,844 |
| Cash | 2,943 | 2,944 | 1,844 | 2,971 | 3,652 | 4,011 |
| Total debt | 13,991 | 12,479 | 13,048 | 12,995 | 13,597 | 15,859 |
| Total liabilities | 21,246 | 19,754 | 20,268 | 21,319 | 22,337 | 25,424 |
| 13,084 | 14,877 | 16,616 | 18,593 | 20,634 | 22,420 | |
| 380 | 382 | 382 | 384 | 386 | 387 | |
| 6.6% | 7.6% | 8.3% | 10.1% | 9.0% | 10.6% | |
| 12.2% | 13.4% | 14.2% | 17.0% | 14.5% | 14.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 3,277 | 3,263 | 2,624 | 3,711 | 4,242 | 5,044 | |
| 487 | 525 | 588 | 575 | 755 | 761 | |
| 2,790 | 2,738 | 2,036 | 3,136 | 3,487 | 4,283 | |
| Dividends paid | 863 | 950 | 1,051 | 1,139 | 1,219 | 1,284 |
| 0 | 0 | – | – | – | – | |
| 142 | 171 | 168 | 205 | 229 | 243 |
Valuation
- 36.3×
- 20.7×
- 2.44
- 5.2×
- 4.7×
- 27.5×
- 20.5×
- 3.6%
- 2.8%
- 1.1%
Profitability
- 64.0%
- 20.1%
- 12.9%
- 22.9%
- 10.8%
- 9.7%
- 15.2%
- 7.2%
- 13.5%
- 6.4%
Growth
- +11.8%
- +14.9%
- +22.8%
- +7.6%
- +0.4%
Financial health
- 1.9×
- 0.71
- 30.7%
- 8.4×
- 1.89
- 1.25
- 0.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 26%of 963
Top 25%of 894
Bottom 36%of 632
Top 46%of 908
Top 32%of 991
What analysts expect
- Average price target
- $395.00
- Range
- $315.00 – $465.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 2.60 | 2.98 | −12.8% |
| Jan 29, 2026 | 4.47 | 4.40 | +1.6% |
| Oct 30, 2025 | 3.19 | 3.13 | +1.9% |
| Jul 31, 2025 | 3.13 | 3.07 | +2.0% |
| May 1, 2025 | 2.84 | 2.71 | +4.8% |
| Jan 28, 2025 | 4.01 | 3.87 | +3.6% |
| Oct 29, 2024 | 2.87 | 2.77 | +3.6% |
| Jul 30, 2024 | 2.81 | 2.79 | +0.7% |
1.1%of the share price, paid each year
On $1,000 invested$11a year at today's yield, before tax
+7.6%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$1.42 in 2015 → $3.40 in 2025
How safe it looks
39.6% of its profit
Room to growStretchedMore than it earns: 30.0%
News
3 Reasons Investors Watch Stryker (SYK)Yahoo Finance · Oct 12, 2026Stryker Launches FDA-Cleared Apple Vision Pro Surgical AppYahoo Finance · Sep 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
39No pass
Philip Fisher
63Pass
Peter Lynch
45No pass
Joel Greenblatt
16No pass
Charlie Munger
48No pass
Terry Smith
51No pass
Questions about Stryker
Is Stryker a good stock to buy?
A solid business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Stryker AI analysis
What does Stryker do?
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. It is in Medical Devices, based in Portage, MI, United States, with 56,000 employees.
Does Stryker pay a dividend?
Yes. At today's price the dividend is 1.1% a year, about 40% of its yearly profit. In 2025 it paid out $1.28 billion in dividends.
Is Stryker stock halal?
Yes. Stryker passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Stryker stock done over the past year?
Down 17.1% over the past twelve months, to $309.64. It traded between $269.75 and $387.46 and is 20.1% below its high.
Who are Stryker's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Edwards Lifesciences and Siemens Healthineers. The peers table on this page compares their profit, growth and price with Stryker's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.